Organization
Octapharma
22 clinical trials
Clinical trial
Nuwiq Dosing and Outcomes In the ManagEment of Women/Girls With Haemophilia A Needing FVIII Treatment for Surgery - an International, Open-label, Non-controlled Study (NuDIMENSION)Status: Not yet recruiting, Estimated PCD: 2025-12-01
Clinical trial
Nuwiq for Perioperative Management Of Patients With Haemophilia A on Emicizumab Regular Prophylaxis Study (NuPOWER)Status: Recruiting, Estimated PCD: 2025-12-01
Clinical trial
Post-marketing Observational Study on the Safety and Efficacy of Fibryga in Congenital Fibrinogen DeficiencyStatus: Recruiting, Estimated PCD: 2027-10-01
Clinical trial
Clinical Study to Investigate the Efficacy, Pharmacokinetics, Immunogenicity and Safety of Wilate in Severe Von Willebrand Disease Patients Under the Age of 6 YearsStatus: Active (not recruiting), Estimated PCD: 2024-12-01
Clinical trial
Phase 3, Double-blind, Placebo-controlled, Multicentre Study on the Efficacy and Safety of Human Plasma Derived Antithrombin (Atenativ) in Heparin-resistant Patients Scheduled to Undergo Cardiac Surgery Necessitating Cardiopulmonary BypassStatus: Not yet recruiting, Estimated PCD: 2026-09-01
Clinical trial
Efficacy and Safety of Octagam 10% Therapy in COVID-19 Patients With Severe Disease ProgressionStatus: Completed, Estimated PCD: 2022-02-01
Clinical trial
Double-blind, Randomized, Placebo-controlled, Prospective Phase III Study Evaluating Efficacy and Safety of Panzyga in Primary Infection Prophylaxis in Patients With Chronic Lymphocytic Leukemia ("PRO-SID" Study)Status: Recruiting, Estimated PCD: 2025-08-01
Clinical trial
Study of Four-factor Prothrombin Complex Concentrate, OCTAPLEX, in Patients With Acute Major Bleeding on Direct Oral Anticoagulant (DOAC) Therapy With Factor Xa InhibitorStatus: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
Post-Marketing Study to Evaluate the Efficacy and Safety of PANZYGA in Pediatric Patients With Chronic Immune Thrombocytopenia (ITP)Status: Active (not recruiting), Estimated PCD: 2024-04-01
Clinical trial
A Multicentre, Prospective, Open-label, Uncontrolled Phase 3 Study to Assess the Efficacy, Safety and Pharmacokinetics of Atenativ in Patients With Congenital Antithrombin Deficiency Undergoing Surgery or DeliveryStatus: Recruiting, Estimated PCD: 2025-06-01
Clinical trial
Multicenter, Prospective, Double-Blinded, Parallel Group, Randomized Phase III Study to Evaluate Safety and Efficacy of Different PANZYGA Dose Regimens in Pediatric Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) PatientsStatus: Recruiting, Estimated PCD: 2026-06-01
Clinical trial
Prospective, Multicentre, Active-control Randomised Trial Comparing 4-factor Prothrombin Complex Concentrate With Frozen Plasma in Bleeding Adult Cardiac Surgical PatientsStatus: Recruiting, Estimated PCD: 2024-08-01
Clinical trial
Multinational, Observational, Retrospective Study to Evaluate Coagulation Changes and the Influence of Antithrombin III Treatment in Patients With Severe COVID-19 InfectionStatus: Completed, Estimated PCD: 2022-09-27
Clinical trial
A Randomized, Open-label, Efficacy and Safety Study of Octaplex and Fresh Frozen Plasma (FFP) in Patients Under Vitamin K Antagonist Therapy With the Need for Urgent Surgery or Invasive ProceduresStatus: Completed, Estimated PCD: 2012-03-01
Clinical trial
Clinical Study to Investigate the Efficacy and Safety of Wilate During Prophylaxis in Previously Treated Patients With Von Willebrand Disease (VWD)Status: Completed, Estimated PCD: 2022-04-23
Clinical trial
A Phase III, Randomized, Double-blind, Multicenter Study to Assess the Efficacy and Safety of OCTAPLEX, a Four-factor Prothrombin Complex Concentrate (4F-PCC), Compared to the 4F-PCC Beriplex® P/N (Kcentra), for the Reversal of Vitamin K Antagonist (VKA) Induced Anticoagulation in Patients Needing Urgent Surgery With Significant Bleeding Risk.Status: Completed, Estimated PCD: 2022-02-23
Clinical trial
A Prospective, Multicenter, Non-Interventional Study Evaluating the Bleeding Incidence in Patients With Von Willebrand Disease Undergoing On-Demand TreatmentStatus: Completed, Estimated PCD: 2021-01-31
Clinical trial
Clinical Phase 3 Study to Monitor the Safety, Tolerability, and Efficacy of Subcutaneous Human Immunoglobulin (CUTAQUIG®) Administered at Modified Dosing Regimens in Patients With Primary Immunodeficiency DiseasesStatus: Completed, Estimated PCD: 2022-01-03
Clinical trial
A Superiority Phase III Study To Compare The Effect of Panzyga Versus Placebo in Patients With Pediatric Acute-onset Neuropsychiatric Syndrome (PANS/PANDAS)Status: Terminated, Estimated PCD: 2024-05-29
Clinical trial
Post Marketing Observational Study on Safety of BALFAXAR® vs. KCENTRA for Reversal of Vitamin K Antagonist Induced Anticoagulation in Adults Undergoing Urgent Surgery or Invasive Procedure.Status: Not yet recruiting, Estimated PCD: 2031-12-31
Clinical trial
Prospective, Multicenter, Randomized, Double-blind, Parallel Group, Placebo- Controlled, Efficacy and Safety Phase 3 Study of an Intravenous Human Plasma- Derived C1 Esterase Inhibitor (C1-INH) Concentrate in Participants With Congenital C1-INH Deficiency for the Treatment and Pre-procedure Prevention of Acute Hereditary Angioedema AttacksStatus: Recruiting, Estimated PCD: 2025-12-01
Clinical trial
Prospective, Open-label, Single-arm, Multicentre Phase 3 Study to Evaluate the Pharmacokinetics, Efficacy, Tolerability, and Safety of Subcutaneous Human Immunoglobulin (Newnorm) in Patients With Primary Immunodeficiency DiseasesStatus: Recruiting, Estimated PCD: 2025-06-01